Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Company profile
Ticker
ZGNX
Exchange
Website
CEO
Stephen Farr
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ZOGENIX INC
SEC CIK
Corporate docs
Subsidiaries
Modis Therapeutics, Inc. • Zogenix Europe Limited • Zogenix GmbH • Zogenix International Limited • Zogenix K.K. • Zogenix ROI Limited • Zogenix SAS • Zogenix S.r.l. ...
IRS number
205300780
ZGNX stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
17 Mar 22
EFFECT
Notice of effectiveness
8 Mar 22
EFFECT
Notice of effectiveness
8 Mar 22
POS AM
Prospectus update (post-effective amendment)
7 Mar 22
POS AM
Prospectus update (post-effective amendment)
7 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Mar 22
Transcripts
ZGNX
Earnings call transcript
2021 Q3
5 Nov 21
ZGNX
Earnings call transcript
2021 Q2
6 Aug 21
ZGNX
Earnings call transcript
2021 Q1
7 May 21
ZGNX
Earnings call transcript
2020 Q4
26 Feb 21
ZGNX
Earnings call transcript
2020 Q3
10 Nov 20
ZGNX
Earnings call transcript
2020 Q2
5 Aug 20
ZGNX
Earnings call transcript
2020 Q1
5 May 20
ZGNX
Earnings call transcript
2019 Q4
2 Mar 20
ZGNX
Earnings call transcript
2019 Q3
8 Nov 19
ZGNX
Earnings call transcript
2019 Q2
6 Aug 19
Latest ownership filings
Financial summary
Quarter (USD) | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 101.18 mm | 101.18 mm | 101.18 mm | 101.18 mm | 101.18 mm | 101.18 mm |
Cash burn (monthly) | 1.65 mm | 5.48 mm | 21.00 mm | 18.67 mm | 13.71 mm | 15.44 mm |
Cash used (since last report) | 45.94 mm | 152.26 mm | 583.62 mm | 519.06 mm | 381.07 mm | 429.21 mm |
Cash remaining | 55.24 mm | -51.08 mm | -482.44 mm | -417.88 mm | -279.89 mm | -328.03 mm |
Runway (months of cash) | 33.4 | -9.3 | -23.0 | -22.4 | -20.4 | -21.2 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|